CG Oncology CGON Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $33.7M+3.7% | $32.49M-28.0% | $45.15M+209% | $14.62M-64.7% | $41.47M-83.9% | ||
| $1.04B+46.9% | $709.67M+11.7% | $635.12M-1.7% | $646.43M-0.1% | $646.96M+33.4% | ||
| $1.28M+85.3% | $688K+33.6% | $515K-8.4% | $562K+62.9% | $345K-55.8% | ||
| $1.49M-4.6% | $1.57M+4.3% | $1.5M— | —— | —— | ||
| $1.1B+45.1% | $759.48M+9.2% | $695.79M+3.4% | $673.03M-4.0% | $701.19M-7.0% | ||
| $15.07M-3.3% | $15.6M+1.7% | $15.33M+5,959% | $253K-4.2% | $264K-2.9% | ||
| $10.3M0.0% | $10.3M0.0% | $10.3M— | —— | —— | ||
| $560K-2.6% | $575K-65.6% | $1.67M— | —— | —— | ||
| $1.14B+43.4% | $791.59M+8.5% | $729.91M+4.1% | $701.45M-3.7% | $728.18M-3.5% | ||
| $8.24M+44.1% | $5.71M-37.8% | $9.19M+29.0% | $7.13M+5.9% | $6.73M+3.3% | ||
| $35.22M+14.2% | $30.84M+1.0% | $30.53M+0.5% | $30.38M+34.2% | $22.64M+6.0% | ||
| $3M0.0% | $3M0.0% | $3M— | —— | —— | ||
| $43.48M+11.5% | $38.99M-7.8% | $42.27M+36.0% | $31.09M+32.7% | $23.42M+9.4% | ||
| $9K+12.5% | $8K0.0% | $8K0.0% | $8K0.0% | $8K0.0% | ||
| -$439.18M-15.9% | -$378.98M-12.2% | -$337.67M-14.9% | -$293.86M-16.4% | -$252.43M-15.8% | ||
| $1.09B+45.1% | $752.6M+9.4% | $687.64M+2.6% | $670.36M-4.9% | $704.76M-3.9% | ||
| $1.14B+43.4% | $791.59M+8.5% | $729.91M+4.1% | $701.45M-3.7% | $728.18M-3.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can CG Oncology cover its short-term obligations?
- Its current ratio is 31.30 — current assets exceed current liabilities.
- Where does CG Oncology's balance sheet data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.